The End of Blockbuster Drugs?

This article is brought to you by Equifund, LLC.

Share on facebook
Share on twitter
Share on linkedin

For more than 30 years, the $1.3 trillion pharmaceutical industry has been driven by one thing…

The never ending quest for the elusive “holy grail” of pharma:

  • A “Blockbuster Drug” that generates more than $1 billion per year in sales.

Which, given how expensive it is to get new drugs to market, is the required payday these companies need to make drug development financially viable.

But there’s a huge problem that comes with Blockbuster Drugs…

As soon as the patent expires, their government granted monopoly expires with it…

But investor expectations of returns don’t!

According to Bloomberg Businessweek…

The prospect of big drugs going off patent—allowing rivals to market their own versions of a popular medicine at a lower price—causes chronic anxiety in the industry. Japan’s Takeda Pharmaceutical Co., which recently bought Shire for $62 billion, has been trying to refill its pipeline since at least 2012, when its top drug, Actos, lost patent protection.

“They need blockbusters. It’s a perpetual chase,” says Ketan Patel, a fund manager at Edentree Investment Management Inc. in London. “The assumption is that every year you’re going to find a fantastic product; it doesn’t work like that.”

Or, put another way, “Big Pharma” – like Venture Capital – is focused on building a “Moonshot Portfolio” of drugs whose returns can make up for all the losers and then some…

But there’s a weird problem with drug development that VC’s don’t have to deal with…

In tech investing, you have the effects of Moore’s Law at play – which states the number of transistors on a microchip doubles about every two years, though the cost of computers is halved.

In biotech, you have the reverse of Moore’s Law known as Eroom’s Law – the cost of developing a new drug roughly doubles every nine years (inflation-adjusted).

According to a 2012 study released by Nature Reviews Drug Discovery…

The past 60 years have seen huge advances in many of the scientific, technological and managerial factors that should tend to raise the efficiency of commercial drug research and development (R&D).

Yet the number of new drugs approved per billion US dollars spent on R&D has halved roughly every 9 years since 1950, falling around 80-fold in inflation-adjusted terms.

And this is, in a nutshell, the “Curse of Blockbuster Drugs” all pharmaceutical companies have to deal with…

They are overly reliant on the success of a small number of drugs, which are getting more expensive to produce.

And as a result, continue to push drug prices higher for people who rely on patented medicine.

Now, to be clear, I don’t know how to solve the problem of expensive drugs…

But it’s still useful to investigate the reasons why drug development costs are so high.

According to the same study, there are four main problems in drug discovery…

Problem #1) The “Cautious Regulator” Problem

It’s easy to say “regulators should ease up and push more things through to reduce cost”…

But when you have high profile disasters – like Thalidomide or Vioxx – they have to be removed from the market and regulators have to clamp down.

Yes, it stifles innovation and reduces competition… but putting out risky drugs with crazy side effects isn’t a good look for anyone.

Problem #2) The “Throw Money At It” Tendency

The other two causes of the Eroom Effect are the ‘throw money at it’ tendency, where additional human and other resources are allocated to R&D.

Some experts argue that strong returns on R&D investment in the past – plus a relatively poor understanding of the stochastic innovation process, and the importance of being first to market – has contributed to the rise in R&D spending in major pharmaceutical companies.

Problem #3) The “Basic Research–Brute Force” Bias

The tendency to overestimate the ability of advances in basic research and brute force screening methods to show a molecule as safe and effective in clinical trials.

Problem #4) The “Better than the Beatles” Problem

The analogy here is simple:

Imagine you had to write new pop songs, and your measure of success was “is it better than the Beatles?”

If that were your score card, there wouldn’t be very many songs written ever again.

Well, Blockbuster Drugs have the same problem…

Eventually, their patents expire… and creating a new drug to replace the best thing you’ve built – and get a new patent – is hard.

Which means it’s going to be extremely difficult to replace that drug when the patent expires!

But, it does open some interesting options biotech firms can explore by going after Orphan Drugs (which are rare diseases or conditions affecting fewer than 200,000 persons in the US).

Which, after nearly four decades of relatively consistent growth, have become a key player in the pharma market and is predicted to rake in $217bn in 2024.

That’s estimated to be more than 18% of overall prescription sales in 2024.

But wait, there’s more…

In 2019, just under half (44%) of new FDA approvals went to orphan drugs.

Better still, the value created by orphan R&D drugs, based on consensus forecasts, is 20 percentage points higher than non-orphan drugs.

And the real cherry on top?

The Orphan Drug Tax Credit – which lets companies claim a 50% tax credit for qualified clinical testing expenses incurred in testing certain drugs for rare diseases or conditions.

The Rise of the Precision Blockbuster?

The blockbuster drug model once reigned supreme…

But thanks to the new innovations in precision medicine, the blockbuster drugs of the future might not be a one size fits all model…

Instead, they might be a collection of tightly targeted therapies that are highly effective and inexpensive to bring to market.

Sincerely,

Jake Hoffberg

Jake Hoffberg – Publisher
Equifund

Like this article? Share it with a friend:

Share on facebook
Share on twitter
Share on linkedin

This article is not an Equifund Crowd Funding Portal Inc communication. It is brought to you by Equifund, LLC.

More Articles:

Don't make another private market investment without reading this...

The 5 Mistakes

investors make that crush returns

Download this free report now:

Just enter your name & email to access this report for free.

By submitting your email address you will receive access to this report and a free subscription to Equifund’s private investment newsletter. You can unsubscribe at any time and read more about our privacy policy here.

More Articles:

Advertisement:

No data was found

Pre-Investment Agreement

The next 8 slides will allow us to process your investment. Note that these next steps are a legal requirement – Thank you for your patience and financial support of this investment opportunity. Jordan Gillissie – CEO

Before we execute the investment, it’s important for us to make sure you’re comfortable and knowledgeable in early stage investing. We want to make sure that you:

    • Received and have reviewed the education materials sent to you.
    • UNDERSTAND; that there are restrictions on your ability to cancel your investment commitment and obtain a return of your investment.
    • KNOW; It may be difficult to resell securities acquired under Regulation Crowdfunding.
    • AGREE; investing in securities offered and sold in reliance on section 4(a)(6) of the Securities Act involves risk. Investors should not invest any funds unless he or she can afford to lose the entire amount of his or her investment. Your investment may not work out, and you must be in a financial condition to bear the loss.
  • Hidden
  • Hidden
  • Hidden
  • Hidden

We are currently upgrading our system. If you click submit and the process does not continue in a few seconds, please refresh this page manually, and click Invest Now again and you should be moved on to the next step.

Complete Your Registration

By verifying your account you agree with our terms of use, privacy policy and pre-dispute arbitration agreement. Please complete the registration process by clicking the link below:

Verify Your Email

Please wait a few minutes while we create your account. An email will be sent to you shortly to confirm your admittance. Should the email be delivered to your spam or promotions folder, we recommend you move it to your inbox and mark Equifund as a safe sender.

If you have not received the email in 5 minutes, please click here to have it resent.

Questions? Our customer service team is always here to help – 1-866-338-3004

Enter your email address to get instant access to the video: